抗HIV-1广谱中和抗体在主动和被动免疫中研究进展  

Recent progress on anti-HIV-1 broadly neutralizing antibodies in active and passive vaccination

作　　者：李岚 欧阳雁玲[2] 殷昌斌[1] 刘巍[1] LI Lan;OUYANG Yan-ling;YIN Chang-bin;LIU Wei(Department of Laboratory Medicine,Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京潞河医院检验科,北京101149 [2]国家开放大学农医学部,北京100039

出　　处：《中国病毒病杂志》2019年第1期58-62,共5页Chinese Journal of Viral Diseases

基　　金：北京市通州区科技计划项目(KJ2017CX039-14)

摘　　要：联合抗逆转录病毒治疗在控制HIV-1感染方面取得了成功,但是尚无法消除病毒储藏库,将导致停药后病毒反弹。大量动物实验研究表明,抗HIV-1广谱中和抗体可以预防HIV-1感染。目前,能够诱导产生广谱中和抗体的疫苗研发尚未成功,HIV-1疫苗仍是未来重要的研究方向。近期在基因工程小鼠中实施顺序免疫接种,能够诱导产生广谱中和抗体的主动免疫应答,另有研究证实体内给予广谱中和抗体的被动免疫亦可作为新的治疗方法。本文讨论了广谱中和抗体在HIV-1治疗中所起的作用,及现阶段在主动和被动免疫研究中的关键突破。Despite the success of combinational antiretroviral therapy in controlling HIV-1infection,the therapy does not eliminate the latent reservoir which is believed to be the source of viral rebound shortly after the discontinuation of standard therapy.Extensive studies in experimental animals have demonstrated that broadly neutralizing antibodies(bNAbs)to HIV-1can prevent infection.However,numerous efforts to elicit broadly neutralizing antibodies were unsuccessful,and the development of such a vaccine remains an important goal.Recently discovered sequential immunization in genetically engineered mice elicited the antibody response toward bNAb development,and recent experiments have demonstrated new therapeutic applications for passively administered bNAbs in vivo.In this review,we discuss the roles that bNAbs might play in HIV-1treatment regimens,and the key breakthroughs to the development of active and passive HIV-1vaccines.

关 键 词：人免疫缺陷病毒1型 广谱中和抗体 主动免疫 被动免疫 

分 类 号：R512.91[医药卫生—内科学]